Skip to content

Study · Systematic review · 2022

6 results

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression.

Lingvay I, Bauer R, Baker-Knight J, Lawson J, Pratley R

The Journal of clinical endocrinology and metabolism1 Apr 2022Cited by 15 (Europe PMC)

PMID34922383 (opens in a new tab)PMCIDPMC9016460 (opens in a new tab)DOI10.1210/clinem/dgab905 (opens in a new tab)PepBankPUB-34922383
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, indirect comparison showed semaglutide 2.0 mg reduced HbA1c more than dulaglutide 3.0 mg.

    In plain wordsIn adults with type 2 diabetes, an indirect comparison found semaglutide 2.0 mg lowered HbA1c more than dulaglutide 3.0 mg.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change vs dulaglutide 3.0 mg
    Study

    n: not reported in source

    Comparator
    Dulaglutide 3.0 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.0 mgAs given in this study (human).

    Measurements

    Estimated treatment difference HbA1c
    −0.44 % points
    vs dulaglutide 3.0 mg

    Source sentences

    Summary
    Semaglutide 2.0 mg significantly reduced HbA1c vs dulaglutide 3.0 mg and 4.5 mg, with estimated treatment differences (ETDs) of -0.44% points (95% credible interval [CrI], -0.68 to -0.19) and -0.28% points (95% CrI, -0.52 to -0.03), respectively.
    2 context sentences
    Summary · context
    We conducted an indirect treatment comparison (ITC) of their effects on glycated hemoglobin (HbA1c) and body weight in patients with type 2 diabetes.
    Summary · context
    Multilevel network meta-regression was conducted, based on a connected evidence network of published results from the A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes 11 trial and individual patient data from the A Research Study to Compare Two Doses…
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, indirect comparison showed semaglutide 2.0 mg reduced HbA1c more than dulaglutide 4.5 mg.

    In plain wordsIn adults with type 2 diabetes, an indirect comparison found semaglutide 2.0 mg lowered HbA1c more than dulaglutide 4.5 mg.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change vs dulaglutide 4.5 mg
    Study

    n: not reported in source

    Comparator
    Dulaglutide 4.5 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.0 mgAs given in this study (human).

    Measurements

    Estimated treatment difference HbA1c
    −0.28 % points
    vs dulaglutide 4.5 mg

    Source sentences

    Summary
    Semaglutide 2.0 mg significantly reduced HbA1c vs dulaglutide 3.0 mg and 4.5 mg, with estimated treatment differences (ETDs) of -0.44% points (95% credible interval [CrI], -0.68 to -0.19) and -0.28% points (95% CrI, -0.52 to -0.03), respectively.
    2 context sentences
    Summary · context
    We conducted an indirect treatment comparison (ITC) of their effects on glycated hemoglobin (HbA1c) and body weight in patients with type 2 diabetes.
    Summary · context
    Multilevel network meta-regression was conducted, based on a connected evidence network of published results from the A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes 11 trial and individual patient data from the A Research Study to Compare Two Doses…
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, indirect comparison showed semaglutide 2.0 mg reduced body weight more than dulaglutide 3.0 mg.

    In plain wordsIn adults with type 2 diabetes, an indirect comparison found semaglutide 2.0 mg lowered body weight more than dulaglutide 3.0 mg.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change vs dulaglutide 3.0 mg
    Study

    n: not reported in source

    Comparator
    Dulaglutide 3.0 mg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.0 mgAs given in this study (human).

    Measurements

    Estimated treatment difference body weight
    −3.29 kg
    vs dulaglutide 3.0 mg

    Source sentences

    Summary
    Semaglutide 2.0 mg also significantly reduced body weight vs dulaglutide 3.0 mg and 4.5 mg with ETDs of -3.29 kg (95% CrI, -4.62 to -1.96) and -2.57 kg (95% CrI, -3.90 to -1.24), respectively.
    2 context sentences
    Summary · context
    We conducted an indirect treatment comparison (ITC) of their effects on glycated hemoglobin (HbA1c) and body weight in patients with type 2 diabetes.
    Summary · context
    Multilevel network meta-regression was conducted, based on a connected evidence network of published results from the A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes 11 trial and individual patient data from the A Research Study to Compare Two Doses…
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, indirect comparison showed semaglutide 2.0 mg reduced body weight more than dulaglutide 4.5 mg.

    In plain wordsIn adults with type 2 diabetes, an indirect comparison found semaglutide 2.0 mg lowered body weight more than dulaglutide 4.5 mg.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change vs dulaglutide 4.5 mg
    Study

    n: not reported in source

    Comparator
    Dulaglutide 4.5 mg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.0 mgAs given in this study (human).

    Measurements

    Estimated treatment difference body weight
    −2.57 kg
    vs dulaglutide 4.5 mg

    Source sentences

    Summary
    Semaglutide 2.0 mg also significantly reduced body weight vs dulaglutide 3.0 mg and 4.5 mg with ETDs of -3.29 kg (95% CrI, -4.62 to -1.96) and -2.57 kg (95% CrI, -3.90 to -1.24), respectively.
    2 context sentences
    Summary · context
    We conducted an indirect treatment comparison (ITC) of their effects on glycated hemoglobin (HbA1c) and body weight in patients with type 2 diabetes.
    Summary · context
    Multilevel network meta-regression was conducted, based on a connected evidence network of published results from the A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes 11 trial and individual patient data from the A Research Study to Compare Two Doses…
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, odds of reaching HbA1c below 7.0% were significantly greater with semaglutide 2.0 mg than with dulaglutide 3.0 mg.

    In plain wordsIn adults with type 2 diabetes, an indirect comparison found more people reached HbA1c below 7.0% with semaglutide 2.0 mg than dulaglutide 3.0 mg.

    Peptide
    Semaglutide
    Outcome
    IncreaseAchieving HbA1c below 7.0% vs dulaglutide 3.0 mg
    Study

    n: not reported in source

    Comparator
    Dulaglutide 3.0 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.0 mgAs given in this study (human).

    Measurements

    Odds ratio
    2.23 ratio
    vs dulaglutide 3.0 mg

    Source sentences

    Summary
    Odds of achieving HbA1c < 7.0% were significantly greater for semaglutide 2.0 vs dulaglutide 3.0 mg (odds ratio [OR]: 2.23 [95% CrI, 1.15-3.90]), whereas this did not reach significance for semaglutide 2.0 mg vs dulaglutide 4.5 mg (OR: 1.58 [95% CrI, 0.82-2.78]).
    2 context sentences
    Summary · context
    We conducted an indirect treatment comparison (ITC) of their effects on glycated hemoglobin (HbA1c) and body weight in patients with type 2 diabetes.
    Summary · context
    Multilevel network meta-regression was conducted, based on a connected evidence network of published results from the A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes 11 trial and individual patient data from the A Research Study to Compare Two Doses…
  6. 06HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, the odds of reaching HbA1c below 7.0% did not differ significantly between semaglutide 2.0 mg and dulaglutide 4.5 mg.

    In plain wordsIn type 2 diabetes, an indirect comparison found no clear difference between semaglutide 2.0 mg and dulaglutide 4.5 mg in reaching HbA1c below 7.0%.

    Peptide
    Semaglutide
    Outcome
    No significant changeAchieving HbA1c below 7.0% vs dulaglutide 4.5 mg
    Study

    n: not reported in source

    Comparator
    Dulaglutide 4.5 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.0 mgAs given in this study (human).

    Measurements

    Odds ratio
    1.58 ratio
    vs dulaglutide 4.5 mg

    Source sentences

    Summary
    Odds of achieving HbA1c < 7.0% were significantly greater for semaglutide 2.0 vs dulaglutide 3.0 mg (odds ratio [OR]: 2.23 [95% CrI, 1.15-3.90]), whereas this did not reach significance for semaglutide 2.0 mg vs dulaglutide 4.5 mg (OR: 1.58 [95% CrI, 0.82-2.78]).
    2 context sentences
    Summary · context
    We conducted an indirect treatment comparison (ITC) of their effects on glycated hemoglobin (HbA1c) and body weight in patients with type 2 diabetes.
    Summary · context
    Multilevel network meta-regression was conducted, based on a connected evidence network of published results from the A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes 11 trial and individual patient data from the A Research Study to Compare Two Doses…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    9 Oct 2026, 18:17 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.